Work

Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial

Year: 2017

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: The Lancet Neurology

DOI: 10.1016/s1474-4422(16)30357-x

Authors: Jacob Elkins, Roland Veltkamp, Joan Montaner, S Claiborne Johnston, Aneesh B Singhal, Kyra Becker, Maarten G Lansberg, Weihua Tang, Ih Chang, Kumar Muralidharan, Sarah Gheuens, Lahar Mehta, Mitchell S V Elkind

Institutions: Biogen (United States), Imperial College London, Vall d'Hebron Institut de Recerca, Instituto de Biomedicina de Sevilla, The University of Texas at Austin, Massachusetts General Hospital, University of Washington, Harborview Medical Center, Stanford Medicine, Stanford University, Columbia University

Language: English

Topic: Acute Ischemic Stroke Management

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Sanofi, Biogen, Regeneron Pharmaceuticals

OpenAlex ID: W2587953391

FWCI: 18.84

Cites: 37

Cited by: 223

Related to: 10